A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex - Related Studies

A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex

This study has been completed.

Study NCT00002163. Last updated on June 23, 2005. Information provided by NIH AIDS Clinical Trials Information Service

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		AIDS Dementia Complex
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Dementia
		Infection

3	More general conditions related to this trial
		Brain Diseases
		Central Nervous System Diseases
		Delirium, Dementia, Amnestic, Cognitive Disorders
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Mental Disorders
		Nervous System Diseases
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Abacavir sulfate

5	Additional drug interventions recognized in this trial
		Abacavir

6	More general drug interventions related to this trial
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antiviral Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Reverse Transcriptase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Glaxo Wellcome